Literature DB >> 22283885

Translating tuberculosis research into global policies: the example of an international collaboration on diagnostics.

A Ramsay1, K R Steingart, J Cunningham, M Pai.   

Abstract

Using the example of an international collaboration on tuberculosis (TB) diagnostics, we mapped the key stages and stakeholders involved in translating research into global policies. In our experience, the process begins with advocacy for high-quality, policy-relevant research and appropriate funding. Following the assessment of current policy and the identification of key study areas, policy-relevant research questions need to be formulated and prioritised. It is important that a framework for translating evidence into policy at the target policymaking level, in this case global, is available to researchers. This ensures that research questions, study designs and research standards are appropriate to the type and quality of evidence required. The framework may evolve during the period of research and, as evidence requirements may change, vigilance is required. Formal and informal multi-stakeholder partnerships, as well as information sharing through extensive networking, facilitate efficient building of a broad evidence base. Coordination of activities by an international, neutral body with strong convening powers is important, as is regular interaction with policy makers. It is recognised that studies on diagnostic accuracy provide weak evidence that a new diagnostic will improve patient care when implemented to scale in routine settings. This may be one reason why there has been poor uptake of new tools by national TB control programmes despite global policy recommendations. Stronger engagement with national policy makers and donors during the research-intopolicy process may be needed to ensure that their evidence requirements are met and that global policies translate into national policies. National policies are central to translating global policies into practice.

Entities:  

Mesh:

Year:  2011        PMID: 22283885     DOI: 10.5588/ijtld.11.0297

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  6 in total

1.  Applied research for better disease prevention and control.

Authors:  Johannes Sommerfeld; Andrew Ramsay; Franco Pagnoni; Robert F Terry; Jamie A Guth; John C Reeder
Journal:  PLoS Negl Trop Dis       Date:  2015-01-08

Review 2.  Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better?

Authors:  Heidi Albert; Ruvandhi R Nathavitharana; Chris Isaacs; Madhukar Pai; Claudia M Denkinger; Catharina C Boehme
Journal:  Eur Respir J       Date:  2016-07-13       Impact factor: 16.671

3.  Roles of monocyte chemotactic protein 1 and nuclear factor-κB in immune response to spinal tuberculosis in a New Zealand white rabbit model.

Authors:  X H Guo; Z Bai; B Qiang; F H Bu; N Zhao
Journal:  Braz J Med Biol Res       Date:  2017-02-20       Impact factor: 2.590

4.  How to implement new diagnostic products in low-resource settings: an end-to-end framework.

Authors:  Melissa Latigo Mugambi; Trevor Peter; Samuel F Martins; Cristina Giachetti
Journal:  BMJ Glob Health       Date:  2018-11-16

5.  Diagnostic Value of Recombinant Heparin-binding Hemagglutinin Adhesin Protein in Spinal Tuberculosis.

Authors:  Feifei Pu; Jing Feng; Fei Niu; Ping Xia
Journal:  Open Med (Wars)       Date:  2020-02-28

6.  Institutional capacity for health systems research in East and Central African schools of public health: knowledge translation and effective communication.

Authors:  Richard Ayah; Nasreen Jessani; Eric M Mafuta
Journal:  Health Res Policy Syst       Date:  2014-06-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.